
'Alien: Earth' Is Surprisingly Cinematic, a Bit Gross and a Whole Lot of Awesome
Of course, I am speaking about Alien: Earth.
It's been about five years since FX officially announced the Noah Hawley project and, now, with the show just days away from premiering (the first two episodes drop on Tuesday, Aug. 12, on Hulu, FX and Disney Plus), I am here to squash your worries. Alien: Earth is good.
In fact, it's pretty epic. Heck, I'd go so far as to say it's the best Alien story I've seen since James Cameron put Sigourney Weaver in a power loader back in 1986.
Needless to say, I have a lot to say about the eight episodes I've seen -- and I'm going to do so as spoiler-free as possible. Still, if you want to avoid any details about the show, I advise you to tread lightly.
Read more: Hulu to Fully Combine With Disney Plus and Expand Globally: What We Know
FX Networks
Alien: Earth does something no other installment of the franchise has dared to do: It puts the majority of the story on Earth. The year is 2120, just two years before Ellen Ripley's (Weaver) fight for survival takes place on the Nostromo.
In this world, five tech corporations govern the people: Prodigy, Weyland-Yutani, Lynch, Dynamic and Threshold. Up until now, we've only heard of Weyland-Yutani. Adding the other companies to the mix and exploring their political conflicts and fight for power opens up the story and broadens things a bit from the usual monster-versus-innocent-crew-members formula we've come to expect from an Alien story.
Timothy Olyphant plays an aging synthetic named Kirsh in Alien: Earth.
FX Networks
The Xenomorph is still very much the focal point of the series, don't get me wrong. However, Alien: Earth introduces a few new concepts to the mix: Cyborgs (humans augmented with machine parts), hybrids (synthetic bodies controlled by human consciousness) and a collection of insidious space insects that add new horrors besides the face-hugging variety.
You can't really replicate the initial shock that audiences felt after watching Alien for the first time. Sure, a chest-bursting sequence in an Alien movie can be unsettling to watch. But these gruesome scenes are expected and have become formulaic. Hawley knows this and that's why he and his team brought an assortment of creepy-crawlies to the mix.
The result is gross and gory; the inclusion of these space bugs delivers a collection of body horror sequences that left me, more than once, shouting in disgust at the TV. That's high praise coming from me.
Babou Ceesay plays Morrow, a cyborg security officer employed by Weyland-Yutani in Alien: Earth.
FX Networks
Building an original world such as this is only as enthralling as the characters who populate it and the talent slate really delivers the emotional stakes on all accounts. While Timothy Olyphant is the biggest name on the call sheet, each of the main players -- Sydney Chandler (who plays Wendy), Alex Lawther (who plays Hermit), Samuel Blenkin (who plays Boy Kavalier) and Babou Ceesay (who plays Morrow) -- delivers tenfold.
Audiences have never seen Olyphant play a character like the synthetic Kirsh. He's enigmatic in his stillness and leaves you regularly guessing whose side he is on. As wonderful as he is, it's Chandler who carries the show. Wendy is the emotional entry point for the audience and probably the most complex of all the characters.
She is also an advanced synthetic human infused with the consciousness of a child. Her youthful discovery of the world around her bumps up against her newfound responsibility to Prodigy, the company in charge of her synth existence. She strives to reconcile her human identity of the past while trying to make sense of her technological one of the present. Yeesh, talk about an identity crisis.
The Alien franchise has regularly pondered whether humanity deserves to survive. The series asks the same question, whether it's in the face of the alien invaders or the corporatations bending the understanding of what it even means to be human.
Sydney Chandler stars as Wendy, an experimental synth, in Alien: Earth.
FX Networks
Transhumanism, mortality, corporate control and the perils of unchecked technological advancements are some of the heady themes explored here. As big as some of these creative swings get, you shouldn't worry: aliens are still killing people.
The more things change, the more they stay the same.
Stylistically, Alien: Earth regularly references the first two Alien movies. That said, there is ample room to create something new and explore uncharted ground in the process. And the show does just that. The result is a program that is grand in scope, and while familiar visuals and aesthetics are featured throughout, Alien: Earth is delightfully different.
This brings me to the Xenomorph. I'm not sure how practical the effects are in reference to the iconic creature (it's clear in some scenes that there's a person inside of a costume), but there are shots featured throughout the show that present the monster in a unique perspective, unlike anything I've seen before. And instead of waiting multiple episodes before the big bad is revealed, it's set loose in the pilot episode.
Through his TV work with Fargo and Legion, Noah Hawley has established a tone and flavor for his projects, and that offbeat energy can most definitely be found here. His fingerprints are all over this show (he even makes an on-screen cameo), and this is mostly a good thing.
That said, if I were to really nitpick, it'd be the slow-burn pacing featured throughout the season that I'd take issue with. Still, that's a minor flaw to me, which is totally made up for with every banging needle drop that closes out each episode.
It's probably evident that I am a huge Alien fan. I get the references and smile every time I see a style note or referential homage. That said, the show is surprisingly low on Easter eggs, which is great. It respects and honors what came before it without getting lost in the minutiae. Alien: Earth has equal appeal to newbies who have never seen an Alien movie and die-hard franchise fanatics like myself.
Sydney Chandler plays Wendy in FX's Alien: Earth on Hulu.
FX Networks
I can honestly say this series is unlike anything I've seen in the Alien universe. It's familiar while also being new; it's different without being destructive to the lore. Alien fans have trudged through one disappointing movie after another to get here. Alien: Earth is a win, and I'm ecstatic. You could even say my chest is bursting with joy. It only took four decades to get here. I guess good things really do come to those who wait.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Jennifer Aniston suggests Matthew Perry's death 'for the better' amid his addiction battle
Jennifer Aniston has opened up about the deep pain she and her Friends co-stars felt while watching Matthew Perry struggle with addiction, admitting they had been 'mourning' him long before his death. This October will mark two years since Perry – who played the sarcastic and beloved Chandler Bing in the hit US sitcom – was discovered dead in the hot tub of his Los Angeles home on October 28, 2023, aged 54. The Los Angeles County Medical Examiner's Office determined that he died from the acute effects of ketamine and ruled his death accidental. Appearing on the September cover of Vanity Fair magazine, Aniston spoke on the late actor's decades-long fight against substance abuse, telling the publication: 'We did everything we could when we could. But it almost felt like we'd been mourning Matthew for a long time because his battle with that disease was a really hard one for him to fight. 'As hard as it was for all of us and for the fans, there's a part of me that thinks this is better. I'm glad that he's out of pain.' Perry's struggles with alcohol and prescription drugs were well documented, both in interviews and in his 2022 memoir Friends, Lovers and the Big Terrible Thing. In the book, he described how his addictions almost cost him his life, and how his castmates – Aniston, Courteney Cox, Lisa Kudrow, Matt LeBlanc and David Schwimmer – rallied around him behind the scenes. Aniston's words echo the sentiment the cast shared in their joint statement following Perry's death, in which they called themselves 'more than just castmates – we are family.' Over the years, Perry credited Aniston with being one of the friends who never gave up on him. She reportedly reached out regularly, offering support even during his most difficult periods. Friends ran for 10 seasons between 1994 and 2004 and remains one of the most popular sitcoms of all time, with Perry's quick-witted one-liners and impeccable comic timing cementing Chandler Bing as a fan favourite. Reflecting on his passing, Aniston said the grief is still raw, but so too is the gratitude for the years they shared together: 'He was a brother. We loved him deeply. And we always will.' The September issue of Vanity Fair hits newsstands on August 19.
Yahoo
7 minutes ago
- Yahoo
‘Remarkable' pancreatic cancer jab offers longer survival hope for patients
Pancreatic cancer patients have been given fresh hope after a new vaccine appeared to slow disease progression and increase survival. Researchers described the findings as 'remarkable' and have already started testing the efficacy of the jab among a larger group of pancreatic and bowel cancer patients. Pancreatic cancer has some of the poorest cancer survival rates because it is often not detected until it is advanced. Many patients see their cancer unremitting, even after undergoing traditional treatments including chemotherapy and radiotherapy. Now a new vaccine has been developed to help harness the body's immune system to find and attack cancer cells. The jab has shown promise in an early trial. Pancreatic and bowel cancers frequently carry a mutation in a gene called KRAS. This mutation plays a key role in tumour growth and scientists developed the jab to recognise and attack KRAS-mutant cancer cells. The jab is a new type of immunotherapy vaccine designed specifically to improve vaccine delivery to the lymph nodes, which act as filters for foreign substances in the body including cancer cells and infections. The phase 1 trial involved 20 patients with pancreatic cancer and five patients with bowel cancer. After an average follow-up time of almost 20 months, 68% of patients had developed strong immune responses specific to mutant KRAS tumour proteins. Though the study showed that some responded more favourably compared to others. Patients who had the strongest immune responses lived longer and stayed cancer free for longer than those with weaker responses. On average pancreatic cancer patients survived about two years and five months after receiving the vaccine, according to the study, which has been published in the journal Nature Medicine. At present, just three in 10 people diagnosed with the condition survive for a year. Meanwhile the average time before the disease returned, also known as recurrence free survival, was more than 15 months. While some cancer jabs are personalised to each patient, this jab, ELI-002 2P, has a single version which can be given to all patients. This 'off-the-shelf' version means that it can be manufactured in bulk and given more rapidly. Study lead Dr Zev Wainberg, from the University of California, Los Angeles, in the US, told the PA news agency: 'Pancreas cancer (patients) even after all standard treatments, such as chemotherapy and radiation, still have very high risks of the cancer coming back. 'Our results show in the group of patients who had profound immune responses (17/25 68%) achieved had longer survival than we have expected in this cancer, quite a remarkable finding to occur in a phase 1 trial.' He added: 'This is the first trial using a new platform, called AMP technology. 'The technology was invented by a material scientist engineer and immunology, Darrel Irvine, in his lab at MIT, and the platform was designed to improve vaccine delivery to lymph nodes which play a special role in the immune response.' Asked about next steps, he added: 'We launched a randomised phase 2 based on the initial results from the Amplify-201 study in January 2024. 'The accrual of the 144 patients participating was very rapid for this trial, which completed enrolment last December, and we are looking forward to the results as follow up continues.' Dr Chris Macdonald, head of research at the charity Pancreatic Cancer UK, said: 'Immunotherapy, and in particular cancer vaccines, hold so much opportunity in the treatment of pancreatic cancer, but so far the opportunity has not been realised. 'However in recent years, this is changing. This study is the latest in a rapidly progressing field. 'This early-stage study takes an important step, showing the effectiveness of an 'off-the-shelf' cancer vaccine, potentially breaking a reliance on having to generate a vaccine specifically for every individual patient. 'This approach saves time and is less costly and resource heavy, meaning more people could potentially benefit. 'The future is bright and if the momentum in this field continues to grow, more people could have the opportunity to benefit from immunotherapy, helping them to live better for longer.' Dr Dani Edmunds, research information manager at Cancer Research UK, added: 'Although we've helped to double cancer survival in the UK in the past 50 years, progress has not been the same for pancreatic cancer which remains hard to treat. 'Therefore, it's promising to see that vaccines could help people with pancreatic and bowel cancer live cancer-free for longer. 'The results suggest that the vaccine can boost the immune system against cancer in some people following standard treatment. 'These people survived and stayed free from disease for longer than people who didn't get as strong an immune boost following vaccination. 'Larger controlled trials are needed to confirm these initial findings about the benefits of the vaccine. 'More research is needed to understand why some people benefit from the vaccine while others don't so that we can make sure we're beating cancer for everyone.'


Gizmodo
8 minutes ago
- Gizmodo
‘Star Trek: Strange New Worlds' Almost Ended With a Movie
Just before the latest season of Star Trek: Strange New Worlds kicked off, we learned that the Enterprise's journey had set its end date: the show would conclude with a fifth and final season. However, that apparently wasn't always going to be the case, and the show nearly ended sooner. That's according to Rebecca Romijn, who plays Una Chin-Riley (a.k.a. Number One) on the show. Speaking this past weekend at the Star Trek convention STLV in Las Vegas, the actress—via TrekCore—revealed that initially, Strange New Worlds would've come to an end after its currently-in-production fourth season, before being capped off with a feature-length movie. According to Romijn, showrunners Henry Alonso Meyers and Akiva Goldsman were able to convince Paramount to change plans, resulting in the six-episode season five. At the very least that means Strange New Worlds fans are getting a little more Star Trek than originally planned (according to TrekCore, Romijn noted that the movie would've been 'just' two hours), even if it still is a truncated season compared to prior ones. But it also speaks to some of the tumult Star Trek has faced in recent years as Paramount has contracted the franchise after years of a streaming renaissance, and the studio itself prepared to seek new ownership (it was made official last week that Skydance's $8 billion takeover of the company had closed). Much of the Star Trek that helped define this new era for the series on streaming TV has wrapped up in the past few years, and with Strange New Worlds joining them in the next few, just one more series remains in production alongside it: Starfleet Academy, which will stream for at least two seasons. What, if any, Trek will come beyond that remains up in the air right now, although the hope of new ownership and a renewed focus on streaming could see a new generation of Trek shows emerge. Right now, much of the franchise's definitive future lies in film, just like Strange New Worlds' almost did. Patrick Stewart has spent the years since the conclusion of Star Trek: Picard suggesting a new film was in the works, and on the theatrical side of things, there's long been the perpetual hope of a fourth 'Kelvin Timeline' Trek film—but there's also Toby Haynes' planned 'origins' film detailing the early years of Starfleet post-First Contact. With all that in mind, a planned streaming movie conclusion to Strange New Worlds at least makes a little more sense. But only a little. After all, despite a rich cinematic legacy, Star Trek fans will likely always insist that the boldly going is just better in a long-form TV format. Who knows—maybe it would've been a better bet than a Section 31 movie turned out to be? Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what's next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.